^
    Back
    Association details:
    Biomarker:TMB-H + PD-L1 overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Lung Cancer
    Title:

    Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors

    Published date:
    07/26/2021
    Excerpt:
    Patients with both high PD-L1 expression and high TMB showed a good response to ICIs with the response rate of 64% and median progression-free survival of 9.0 months despite of small population.
    DOI:
    10.1016/j.lungcan.2021.07.015
    Test:
    PD-L1 IHC 22C3 pharmDx, VENTANA PD-L1 (SP263) Assay, VENTANA PD-L1 (SP142) Assay, PD-L1 IHC 28-8 pharmDx
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR 2021
    Title:

    490 - A very high tumor mutational burden (TMB) is associated with improved efficacy of PD-(L)1 inhibition across different PD-L1 expression subgroups and a distinct immunophenotype in NSCLC

    Published date:
    03/10/2021
    Excerpt:
    TMB cut-off for objective response rate (ORR) in two independent cohorts (DFCI and MSKCC) of pts with NSCLC treated with ICI….A TMB ≥90th percentile correlated with longer PFS/OS among NSCLCs with PD-L1 levels ≥50%...
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2020
    Title:

    MA08.06 - Stratifying PD-L1 Expression Level Based on Multimodal Genomic Features for the Prediction of Immunotherapy Benefit in NSCLC

    Published date:
    01/12/2021
    Excerpt:
    ...a combination of our model with TMB showed 52% of patients with both TMB high and predicted PD-L1 high benefited from ICIs treatment...We also find the predicted PD-L1 expression levels combined with TMB may help to identify patients who are most likely to respond to ICIs treatment...